doses <100 mgSerious - Use Alternative (1)fluoxetine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.deutetrabenazineMonitor Closely (2)deutetrabenazine and fluoxetine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation). fluoxetine will increase the level or effect of deutetrabenazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Strong CYP2D6 inhibitors increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine by approximately 3-fold. Do not exceed 18 mg/dose and 36 mg/day of deutetrabenazine if coadministered with strong CYP2D6 inhibitors.dexfenfluramineMonitor Closely (2)fluoxetine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. fluoxetine will increase the level or effect of dexfenfluramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.dexmethylphenidateMinor (1)dexmethylphenidate increases effects of fluoxetine by decreasing metabolism. Minor/Significance Unknown.dextroamphetamineMonitor Closely (2)fluoxetine will increase the level or effect of dextroamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. fluoxetine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.dextroamphetamine transdermalMonitor Closely (2)fluoxetine, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s). fluoxetine will increase the level or effect of dextroamphetamine transdermal by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor.dextromethorphanSerious - Use Alternative (2)fluoxetine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.diazepamMonitor Closely (1)fluoxetine will increase the level or effect of diazepam by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.diazepam intranasalMonitor Closely (2)fluoxetine will increase the level or effect of diazepam intranasal by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Strong or moderate CYP2C19 inhibitors may decrease rate of diazepam elimination, thereby increasing adverse reactions to diazepam. diazepam intranasal, fluoxetine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.dichlorphenamideMonitor Closely (1)dichlorphenamide and fluoxetine both decrease serum potassium. Use Caution/Monitor.diclofenacMonitor Closely (2)fluoxetine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. fluoxetine, diclofenac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.difelikefalinMonitor Closely (1)difelikefalin and fluoxetine both increase sedation. Use Caution/Monitor.diflunisalMonitor Closely (1)fluoxetine, diflunisal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.dihydroergotamineMonitor Closely (1)fluoxetine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.dihydroergotamine intranasalMonitor Closely (1)fluoxetine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.diphenhydramineMinor (1)diphenhydramine will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.disopyramideSerious - Use Alternative (1)disopyramide and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug.dofetilideMonitor Closely (1)dofetilide and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.dolasetronMonitor Closely (1)dolasetron and fluoxetine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)dolasetron, fluoxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.donepezilMonitor Closely (2)fluoxetine will increase the level or effect of donepezil by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. donepezil and fluoxetine both increase QTc interval. Use Caution/Monitor.dosulepinSerious - Use Alternative (1)fluoxetine and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.doxepinMonitor Closely (1)doxepin and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (2)fluoxetine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.dronedaroneMonitor Closely (1)dronedarone and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.Minor (1)dronedarone will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.droperidolMonitor Closely (1)droperidol and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.duloxetineSerious - Use Alternative (2)duloxetine and fluoxetine both increase serotonin levels. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.Minor (1)duloxetine will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.edoxabanMonitor Closely (1)fluoxetine increases effects of edoxaban by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.efavirenzMonitor Closely (1)efavirenz and fluoxetine both increase QTc interval. Use Caution/Monitor.eletriptanMonitor Closely (1)eletriptan and fluoxetine both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (1)fluoxetine, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.eliglustatContraindicated (1)fluoxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.Monitor Closely (1)eliglustat increases levels of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.Serious - Use Alternative (1)eliglustat and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug.eluxadolineMonitor Closely (1)fluoxetine increases levels of eluxadoline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2D6 inhibitors.elvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (2)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events. elvitegravir/cobicistat/emtricitabine/tenofovir DF decreases levels of fluoxetine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.encainideMonitor Closely (1)fluoxetine will increase the level or effect of encainide by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.encorafenibSerious - Use Alternative (1)encorafenib and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid with drugs known to prolong QT interval.entrectinibSerious - Use Alternative (1)fluoxetine and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.epinephrineMonitor Closely (1)epinephrine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.epinephrine racemicMonitor Closely (1)epinephrine racemic and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.ergotamineMonitor Closely (1)fluoxetine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.eribulinMonitor Closely (1)eribulin and fluoxetine both increase QTc interval. Use Caution/Monitor.erythromycin baseMonitor Closely (1)erythromycin base and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin ethylsuccinateMonitor Closely (1)erythromycin ethylsuccinate and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin lactobionateMonitor Closely (1)erythromycin lactobionate and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin stearateMonitor Closely (1)erythromycin stearate and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.escitalopramMonitor Closely (1)escitalopram and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (2)escitalopram and fluoxetine both increase serotonin levels. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug.esomeprazoleMinor (1)fluoxetine will increase the level or effect of esomeprazole by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.ethacrynic acidMinor (1)ethacrynic acid, fluoxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.ethotoinMonitor Closely (1)fluoxetine will increase the level or effect of ethotoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.etodolacMonitor Closely (1)fluoxetine, etodolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.etravirineMonitor Closely (1)fluoxetine will increase the level or effect of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.ezogabineMonitor Closely (1)ezogabine and fluoxetine both increase QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.Serious - Use Alternative (1)fluoxetine will increase the level or effect of fedratinib by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied.fenbufenMonitor Closely (1)fluoxetine, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fenfluramineMonitor Closely (2)fenfluramine, fluoxetine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. fluoxetine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenoprofenMonitor Closely (1)fluoxetine, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fentanylSerious - Use Alternative (1)fentanyl, fluoxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl intranasalSerious - Use Alternative (1)fentanyl intranasal, fluoxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transdermalSerious - Use Alternative (1)fentanyl transdermal, fluoxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transmucosalSerious - Use Alternative (1)fentanyl transmucosal, fluoxetine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fesoterodineMonitor Closely (1)fluoxetine will increase the level or effect of fesoterodine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.fexinidazoleSerious - Use Alternative (1)fexinidazole and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.fezolinetantContraindicated (1)fluoxetine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsfinerenoneMonitor Closely (1)fluoxetine will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.fingolimodMonitor Closely (1)fingolimod and fluoxetine both increase QTc interval. Use Caution/Monitor.fish oil triglyceridesMonitor Closely (1)fish oil triglycerides will increase the level or effect of fluoxetine by anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants.flecainideMonitor Closely (1)flecainide and fluoxetine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)fluoxetine will increase the level or effect of flecainide by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.flibanserinMonitor Closely (1)fluoxetine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.fluconazoleMonitor Closely (1)fluconazole and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazineSerious - Use Alternative (2)fluphenazine and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of fluphenazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.flurbiprofenMonitor Closely (2)fluoxetine will increase the level or effect of flurbiprofen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. fluoxetine, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fluvastatinMonitor Closely (1)fluoxetine will increase the level or effect of fluvastatin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.fluvoxamineSerious - Use Alternative (1)fluvoxamine and fluoxetine both increase serotonin levels. Avoid or Use Alternate Drug.fondaparinuxMonitor Closely (1)fluoxetine increases effects of fondaparinux by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.formoterolMonitor Closely (1)fluoxetine and formoterol both increase QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with